Should I Buy UTHR? UTHR 2026 Analysis

Should You Buy United Therapeutics Corp (UTHR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

467.700

1 Day change

0.09%

52 Week Range

519.990

Analysis Updated At

2026/01/26

United Therapeutics Corp (UTHR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock demonstrates strong financial growth, positive analyst sentiment with upward price target revisions, and a favorable options sentiment. Despite neutral technical indicators, the company's robust fundamentals and growth potential make it a solid long-term investment.

Technical Analysis

The MACD histogram is -2.99, below 0, and negatively contracting, indicating a lack of bullish momentum. RSI is at 32.982, in the neutral zone, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support is at 459.721, and resistance is at 488.477. Overall, technical indicators are neutral.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low Option Volume Put-Call Ratio (0.43) reflects a higher call volume, suggesting bullish sentiment. The Open Interest Put-Call Ratio of 1.24 indicates more open interest in puts than calls, but the overall sentiment leans positive given the volume data.

Technical Summary

Sell

Buy

Positive Catalysts

Strong financial performance in Q3 2025, with revenue up 6.76% YoY, net income up 9.58% YoY, and EPS up 12.05% YoY.
Positive analyst sentiment, with multiple price target increases and Buy ratings.
Potential for Tyvaso market expansion and partnerships, as highlighted by analysts.
Stock trend analysis indicates a 70% chance of a 3.59% increase in the next month.

Neutral/Negative Catalysts

Gross margin dropped by 1.71% YoY, indicating slight pressure on profitability.
No recent news or significant insider/hedge fund activity, which may limit immediate momentum.

Financial Performance

In Q3 2025, United Therapeutics reported revenue of $799.5M, up 6.76% YoY, net income of $338.7M, up 9.58% YoY, and EPS of 7.16, up 12.05% YoY. Gross margin dropped slightly to 87.38%, down 1.71% YoY. Overall, the company demonstrated strong growth trends, particularly in revenue and profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on UTHR, with multiple price target increases in recent months. UBS raised its target to $645, Jefferies to $575, and RBC Capital to $587, all maintaining Buy or Outperform ratings. Analysts highlight Tyvaso's growth potential and the company's openness to partnerships as key drivers for future performance.

8 Analyst Rating

Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 534.5 USD with a low forecast of 423 USD and a high forecast of 645 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

3 Hold

0 Sell

Moderate Buy

Current: 467.300

Low

423

Averages

534.5

High

645

Current: 467.300

Low

423

Averages

534.5

High

645

UBS

Buy

maintain

$600 -> $645

AI Analysis

2026-01-06

Reason

UBS

Price Target

$600 -> $645

AI Analysis

2026-01-06

maintain

Buy

Reason

UBS raised the firm's price target on United Therapeutics to $645 from $600 and keeps a Buy rating on the shares. The Biotech sector enters 2026 on a cautiously optimistic note, the analyst tells investors in a research note. While capital absorption from secondary offerings is a concern, over $47B of pending capital from potential M&A could offset this, though sustained outperformance will likely require M&A activity to continue outpacing secondaries and IPOs, the firm says.

UBS

Buy

maintain

$580 -> $600

2025-11-06

Reason

UBS

Price Target

$580 -> $600

2025-11-06

maintain

Buy

Reason

UBS raised the firm's price target on United Therapeutics to $600 from $580 and keeps a Buy rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for UTHR

Unlock Now

UTHR Should I Buy

UTHR Should I Buy

Should You Buy United Therapeutics Corp (UTHR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch